Krsnaa Diagnostics Approves FY26 Financial Results and Recommends Dividend

Krsnaa Diagnostics Approves FY26 Financial Results and Recommends Dividend​

Krsnaa Diagnostics Limited (KDL) has announced the approval of its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company's Board of Directors also recommended a final dividend for the financial year 2025-26.

During the board meeting held on May 25, 2026, the Board approved the audited standalone and consolidated financial results, along with the audit reports issued by the Statutory Auditors. The statutory auditors issued audit reports with an unmodified opinion on the results.

In a key corporate action, the Board recommended a final dividend of INR 2/- per equity share of face value INR 5/- each, for the financial year 2025-26. This dividend recommendation is subject to the approval of the company's members at the ensuing Annual General Meeting.

The board meeting also sanctioned several auditor appointments and re-appointments for the financial year 2026-27, including M/s Kirtane & Pandit LLP Chartered Accountants as the Statutory Auditors; M/s Mahajan & Aibara Chartered Accountants LLP as the Internal Auditor; Harshad S. Deshpande & Associates Cost Accountants as the Cost Auditors; and M/s V. A. Dudhedia and Co., Chartered Accountants as the Tax Auditors for Financial Year 2025-26.

Financial Performance Summary​

The company released detailed financial statements, providing figures for both standalone and consolidated operations.

Standalone Financial Results​

The audited standalone annual financial results for the year ended March 31, 2026, and the audited balance sheet and cash flow statements for the same period are available.

Statement of Audited Standalone Financial Results (INR Million, except earnings per share):


(Note: All figures are in INR Million, except earnings per share.)

Consolidated Financial Results​

For the group, the total income reached 8,161.64 INR Million for the year ended March 31, 2026, compared to 7,426.95 INR Million in the previous year.

Statement of Audited Consolidated Financial Results (INR Million, except earnings per share):


(Note: All figures are in INR Million, except earnings per share.)

Key Financial Updates and Observations​

Dividend and Audit: The board also recommended a final dividend of Rs 2.00 per equity share (face value Rs 5) for the year ended March 31, 2026, contingent on shareholder approval.

Investee Gain (Consolidated): The Holding Company recognized a resultant gain of INR 259.52 million (net of deferred tax - INR 222.41 million) in the consolidated Other Income. This gain relates to the derecognition of the investment in Apulki Healthcare Private Limited, following the cessation of significant influence due to a fresh issue of shares by the investee Company.

Tax Assessment Proceedings: The company noted that the Income Tax authorities have passed assessment orders for several years (AY 2017-18 to AY 2023-24) citing undisclosed income and disallowed deductions, resulting in a demand order of INR 626.90 million. The company has filed appeals against these orders, and management believes the demand orders will not materially impact the financial position for the year ended March 31, 2026.

Cash Flow: Both standalone and consolidated cash flow statements highlight significant capital expenditure, with total purchases of property, plant and equipment and other intangible assets recorded in the millions for both March 31, 2026, and the preceding year.

Outstanding Dues: As of March 31, 2026, the total outstanding dues of creditors other than micro enterprise and small enterprise stood at 623.51 INR Million in the consolidated results.

KRSNAA Stock Price Movement​

Krsnaa Diagnostics Limited slipped 2.23% on Monday, settling at ₹553.85 in session trading. The stock saw a total volume of 65,630 shares traded during the session.